SUMMARY: Lumavita’s LMV-601, an investigational PC-PLC inhibitor, reduced expression of high-risk human papillomavirus (HPV) types 16, 18, and 31, and over time improved pre-cancerous cervical cell abnormalities in a laboratory study, researchers reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston.

Background: We have previously found that the PC-PLC inhibitor LMV-601 inhibits transcription of episomal HPV-31 genomes in premalignant transformed human keratinocytes (CIN 612 9E HPV-31 infected cervical epithelial cells). Concomitantly, HPV DNA replication stopped and with prolonged treatment cells were cured from HPV, lost their transformed phenotype and finally became senescent [Amtmann E. et al., … Read More >